Conventional Synthetic Strategies and Structure–Activity Relationships of Imidazole–Thiadiazole Hybrid Scaffolds: A Comprehensive Review of Their Biological Properties

Nitrogen- and sulphur-containing five-membered heterocycles occupy a disproportionately large share of clinically used small-molecule drugs relative to their structural simplicity. Among these, imidazole and 1,3,4-thiadiazole are two of the most extensively studied ring systems, each carrying a long track record of pharmacological relevance on its own. Imidazole is the core of histidine and histamine, and its synthetic derivatives range from antifungal agents such as ketoconazole and clotrimazole to antiprotozoal drugs such as metronidazole and tinidazole, as well as several angiotensin II receptor antagonists and proton pump inhibitors. The ring is planar, moderately basic, capable of both hydrogen-bond donation and acceptance, and metabolically adaptable, all of which make it an attractive building block for drug design. 1,3,4-Thiadiazole, in turn, is valued for the so-called 'sulphur bridge' effect: the ring's two nitrogen atoms and one Sulphur atom create a mesoionic-like electronic character that improves membrane permeability while retaining reasonable aqueous solubility. Marketed drugs containing this ring include the carbonic anhydrase inhibitor acetazolamide, the diuretic methazolamide, and the antibacterial sulfamethizole, and countless additional analogues have been explored for antimicrobial, anticonvulsant, antitubercular, and anticancer applications. The rationale for combining these two heterocycles into a single hybrid molecule follows the well-established molecular hybridisation strategy in medicinal chemistry, in which two or more pharmacophoric fragments are fused, linked, or embedded within one scaffold in the hope of achieving additive or synergistic biological effects, improved target selectivity, or a more favourable pharmacokinetic profile than either parent fragment could achieve alone. Two broad hybrid architectures dominate the literature: fused bicyclic systems, most commonly the imidazo[2,1-b][1,3,4]thiadiazole ring system in which the two rings share a bridgehead nitrogen and sulphur atom, and linked hybrids, in which an imidazole ring and a separately substituted 1,3,4-thiadiazole ring are connected through a short spacer such as a hydrazone (-CH=N-NH-), amide (-CO-NH-), or thioether (-S-CH2-) bridge. Over the past decade, both architectures have been explored intensively for a remarkably wide spectrum of biological activities, and several independent laboratories have converged on similar substitution trends even while pursuing different disease targets. This convergence suggests that certain structural features of the imidazole-thiadiazole scaffold are genuinely privileged rather than incidental to any single study. The present review gathers this body of work, organises it by both synthetic strategy and biological activity, and attempts to extract the SAR generalisations that carry across activity classes. It is worth clarifying at the outset the scope and terminology adopted here, since the phrase 'imidazole-thiadiazole hybrid' has been used somewhat loosely across the primary literature to describe at least two structurally distinct families. The first, and historically older, family comprises fused bicyclic systems in which ring closure creates a single, continuous aromatic system, most commonly the imidazo[2,1-b][1,3,4]thiadiazole framework introduced in Section 1 above. The second family comprises what might be more precisely termed conjugated or tethered hybrids, in which two intact, independently aromatic rings are joined by a short covalent bridge but retain their own separate electronic identity. Although both families are frequently discussed together in the literature under the general 'imidazole-thiadiazole' heading, and are treated together in this review for that reason, it is important for readers to keep the distinction in mind when comparing SAR conclusions across studies, since a substituent effect that holds for the fused, fully conjugated bicyclic system does not automatically transfer to a flexibly tethered analogue, and vice versa. Where the distinction materially affects the interpretation of a finding, it is noted explicitly in the relevant subsection below. The present review addresses that gap. It first outlines the conventional (non-metal-catalysed, reagent-based) synthetic routes that dominate the literature for assembling the bicyclic core, since almost every biological study surveyed here relies on some variant of the same two-step sequence. It then draws together SAR observations across the major therapeutic areas in which the scaffold has been tested, integrates the available computational docking and ADME data, and closes with a discussion of the synthetic and pharmacokinetic bottlenecks that any future hit-to-lead campaign on this chemotype will need to address.

2. Molecular Architecture Of The Imidazo [2,1-B][1,3,4] Thiadiazole Core:

The bicyclic core consists of a 1,3,4-thiadiazole ring (positions 1–4, with sulphur at position 1) fused through a bridgehead nitrogen (N-7a) to an imidazole ring (positions 5–7). Two aryl-bearing carbons, C-2 on the thiadiazole side and C-6 on the imidazole side, are available for structural modification since the fusion nitrogen is shared by both rings and lacks a substituent. Because the two positions are installed through chemically distinct building blocks — an aromatic carboxylic acid or nitrile for C-2, and an α-haloketone for C-6 — medicinal chemists can vary each substituent independently, which is the principal reason the scaffold has proved so adaptable across unrelated target classes.

Figure 1. Numbering and ring fusion of the imidazo[2,1-b][1,3,4]thiadiazole core. C-2 (thiadiazole ring) and C-6 (imidazole ring) are the two principal sites of aryl substitution; the bridgehead N-7a is common to both rings.

3. Conventional Synthetic Strategies:

Despite the growing interest in energy-efficient and solvent-minimised protocols, the majority of imidazole-thiadiazole hybrids reported in the literature over the last decade have still been prepared through conventional, thermally driven organic transformations, generally carried out under reflux in polar solvents such as ethanol, dimethylformamide, or glacial acetic acid. These conventional routes remain attractive because they are operationally simple, scale readily, and tolerate a broad range of functional groups without specialised equipment.

3.1 Thiosemicarbazide cyclisation to 1,3,4-thiadiazoles:

The most common entry point to the 1,3,4-thiadiazole ring begins with a carboxylic acid or acid chloride, which is converted to the corresponding acid hydrazide and then reacted with carbon disulfide/potassium hydroxide or directly with thiosemicarbazide to generate a thiosemicarbazide or dithiocarbazate intermediate. Oxidative or acid-catalysed cyclodehydration of this intermediate, typically using concentrated sulfuric acid, phosphorus oxychloride, or polyphosphoric acid, then closes the five-membered ring to deliver the 2-amino-5-substituted-1,3,4-thiadiazole. This 2-amino group is subsequently the principal handle used to install the imidazole-bearing fragment, either through direct condensation with an imidazole-carbaldehyde to form a Schiff base (hydrazone) linkage, or through acylation with an imidazole-carboxylic acid derivative to form an amide-linked hybrid.

3.2 Hantzsch-type cyclisation to fused imidazo[2,1-b][1,3,4]thiadiazoles:

When a fused bicyclic system is the synthetic target, the standard route proceeds through alkylation of 2-amino-5-substituted-1,3,4-thiadiazole with an α-haloketone (most often a substituted phenacyl bromide generated in situ from the corresponding acetophenone and bromine or N-Bromo succinimide). The exocyclic amino nitrogen attacks the electrophilic carbon of the α-haloketone, and subsequent intramolecular cyclodehydration closes the imidazole ring onto the thiadiazole nitrogen, furnishing the bicyclic imidazo[2,1-b][1,3,4]thiadiazole core in a single pot. This Hantzsch-type annulation has been used consistently since the 1950s and remains the backbone of essentially every fused-ring hybrid reported in the last ten years, with variation introduced mainly through the choice of aryl substituent on the phenacyl bromide and through further functionalisation at the resulting C-5 position of the newly formed imidazole ring, most commonly by Vilsmeier-Haack formylation followed by condensation with active methylene or amine nucleophiles.

Scheme:1

Two-step Conventional Route to 2,6-Diaryl Imidazo[2,1-b][1,3,4]thiadiazoles

Step 1: Synthesis of 5-Aryl-1,3,4-thiadiazol-2-amine

3.3 Process refinements: microwave and solvent-minimised variants: 

Although the present review centres on conventional thermal methods, it is worth noting that many of the same cyclisation and condensation steps described above have also been adapted to microwave irradiation, ultrasound activation, and catalyst- or solvent-free grinding protocols, generally with the effect of shortening reaction times from several hours to a few minutes and improving isolated yields by ten to twenty percentage points. These process refinements do not change the underlying bond-forming chemistry described in Sections 2.1-2.3; rather, they accelerate the same cyclocondensation and alkylation steps. Where a microwave-assisted variant of a conventional route has been reported for the imidazo[2,1-b][1,3,4]thiadiazole core specifically, comparative greenness assessments indicate substantially reduced energy consumption and waste generation relative to the classical reflux protocol, without loss of the product's structural fidelity as confirmed by matching spectroscopic data.

4. STRUCTURE–ACTIVITY RELATIONSHIP:

The scaffold has been screened against such a wide range of targets, its SAR is best organised by therapeutic area rather than by substituent alone.

R1 (Thiadiazole aryl / basic chain)

• Aromatic R1 (phenyl, chlorophenyl, methoxyphenyl) supports anti-inflammatory and antimicrobial activity.
• Basic amine tail (Et₂N-, piperidinyl) is essential for anti-virulence potency.

R2 (Imidazole aryl)

• Electron-withdrawing groups (CF₃, Br, NO₂, Cl) enhance COX-2 affinity and anticancer potency.
• Methoxy/para-tolyl substituents exhibit milder activity.

Linker & Distal Substituent Effects (Piperidine/Side-Chain Series)

• A three-methylene spacer between the amide and a tertiary amine provides optimal potency.
• Two-methylene spacers markedly reduce or abolish activity (matched-pair comparisons).
• 4-Substituted piperidine outperforms the corresponding 3-substituted isomer.
• Removing the basic nitrogen (e.g., isopentyl analogue) eliminates activity, confirming that electrostatic/ionic interaction with the target protein is indispensable.

Figure 4. Representative EC50 values (Ca2+-influx assay, U937 cells) illustrating how the linker length and terminal amine of the C-2 piperidine-4-carboxamide side chain govern potency against staphylococcal α-hemolysin; data summarised from a recently reported 18-compound analogue series.

X-ray crystallography of the most active compound bound to α-hemolysin revealed that the bicyclic head group occupies a hydrophobic pocket formed between the toxin's amino-latch and prestem domains, engaging in a single hydrogen bond to the backbone amide of a tyrosine residue and a pi-stacking contact with a histidine side chain, while the basic side chain projects away from the core to contact a neighbouring toxin monomer at a site that, in the heptameric pore, would otherwise bind membrane phospholipid head groups. This dual-contact binding mode — stabilising the toxin's inactive, monomeric conformation while simultaneously blocking a phospholipid-binding groove — offers a mechanistic explanation for why the basic side chain identified in the SAR study is not merely a solubilising group but an integral pharmacophoric element, and it illustrates how the same core scaffold that supports COX-directed anti-inflammatory activity in one context can be redirected toward an entirely different, antivirulence mechanism simply by relocating the site of substitution and appending an appropriately spaced amine. The compound class was also reported to be chemically robust and metabolically stable: high plasma protein binding (>96% in both mouse and human plasma), full stability at acidic and neutral pH, only modest lability at pH 9, and low intrinsic clearance in mouse and human liver microsomes were all documented for the lead compound, indicating that — notwithstanding a cellular potency in the single-digit micromolar range that remains well short of the low-nanomolar benchmarks achieved with unrelated quinoxalinedione-based Hla inhibitors from the same research group — the scaffold's physicochemical behaviour is compatible with further lead optimisation.

5.5 Antitubercular activity:

The imidazo[2,1-b][1,3,4]thiadiazole core has an especially long history in antitubercular drug discovery, dating to early work establishing that 2-sulfonamido- and 2-trifluoromethyl-6-arylimidazo[2,1-b]-1,3,4-thiadiazoles could inhibit Mycobacterium tuberculosis H37Rv growth in the microplate Alamar Blue assay at low micromolar concentrations. More recent series have built on this foundation by exploring catechol-substituted and hydroxybenzene-substituted analogues, which combine antitubercular activity with useful antioxidant behaviour, and by systematically comparing phenyl- versus 4-chlorophenyl-substitution at the C-6 position of the bicyclic core. The general SAR conclusion emerging from this body of work is that retention of a sulphonamide or trifluoromethyl group is important for potency, most plausibly because these groups mimic the sulphonamide-based pharmacophore of established antitubercular and antibacterial folate-pathway inhibitors, while additional lipophilic aryl substitution improves cell-wall penetration in the notoriously impermeable mycobacterial envelope.

5.6 Antidiabetic activity (enzyme inhibition)

Antidiabetic evaluation of this scaffold has grown substantially over the last five years, largely through in vitro inhibition of α-glucosidase and α-amylase, the two carbohydrate-hydrolysing enzymes targeted by clinically used agents such as acarbose. A multitarget de novo design study evaluating a library of twenty-four imidazole-thiadiazole compounds reported potent inhibitory activity against α-glucosidase, α-amylase, acetylcholinesterase, and butyrylcholinesterase, with several derivatives reaching low-micromolar IC50 values, alongside meaningful antioxidant capacity measured by CUPRAC, FRAP, and DPPH assays. Multicomponent-derived 1,3,4-thiadiazole-thiazolidin-4-one hybrids have likewise shown dual α-glucosidase/α-amylase inhibition exceeding that of acarbose in several analogues. Docking studies in these reports converge on a hydrogen-bonding network between the thiadiazole nitrogen atoms and catalytic aspartate or glutamate residues in the enzyme active site, with additional stabilisation from aromatic stacking contributed by the imidazole ring, offering a structural rationale for why hydroxylated aryl substituents, which add further hydrogen-bond donors, tend to outperform purely lipophilic analogues in this activity class specifically.

5.7 Antioxidant activity:

Antioxidant capacity is frequently reported as a secondary activity alongside antimicrobial or antitubercular evaluation for this scaffold, reflecting the ease of incorporating a DPPH radical-scavenging assay into an existing screening workflow. Catechol- and resorcinol-substituted imidazo[2,1-b][1,3,4]thiadiazoles have shown the strongest radical-scavenging activity among reported series, consistent with the well-established structure-activity relationship linking phenolic hydroxyl count and position to hydrogen-atom-transfer antioxidant mechanisms. Several of these same catechol-bearing analogues have also displayed useful antitubercular and antibacterial activity, suggesting that this particular substitution pattern may represent a genuinely multifunctional pharmacophore rather than two independently optimised features.

5.8 Antiparasitic and antiprotozoal activity:

A smaller but mechanistically distinct body of work has explored imidazole-1,3,4-thiadiazole hybrids as antiprotozoal agents against Trypanosoma cruzi and Leishmania donovani, the causative organisms of Chagas disease and visceral leishmaniasis respectively. These compounds are typically designed by molecular hybridisation of the nitroimidazole pharmacophore found in established antiprotozoal drugs such as metronidazole and benznidazole with a thiadiazole fragment bridged through a p-aminobenzoate linker. Several analogues from this series reduced parasite proliferation by approximately fifty percent relative to untreated controls in vitro, exceeding the potency of benznidazole and approaching that of nifurtimox within the same assay, while retaining the 5-nitro substituent on the imidazole ring, which SAR analysis indicates is essential for activity, most likely because nitro-group bio reduction under the parasite's characteristic low-oxygen intracellular environment generates the cytotoxic radical species responsible for the observed antiparasitic effect.

5.9 Anticonvulsant and other central nervous system activities:

Anticonvulsant testing of imidazo[2,1-b][1,3,4]thiadiazole derivatives, generally carried out using the maximal electroshock or pentylene tetrazole-induced seizure models in rodents, has been reported intermittently throughout the literature surveyed here, generally as one activity among a broader multi-assay screening panel rather than as the primary focus of a dedicated study. Where reported, activity has correlated loosely with lipophilicity, consistent with the blood-brain-barrier penetration requirements common to CNS-active compounds, though the sample size of dedicated anticonvulsant studies on this specific hybrid scaffold remains too small to support a confident, generalisable SAR statement at this time.

6. Molecular Docking and In Silico Correlation With SAR

Molecular docking has become a near-universal companion technique to in vitro evaluation in the literature on this scaffold, and its findings generally reinforce, rather than contradict, the empirical SAR trends described above. Across the anticancer, antitubercular, and antidiabetic literature reviewed here, docking studies consistently identify a small set of recurring interaction types: hydrogen bonding from the thiadiazole ring nitrogens or an adjacent amino/hydroxyl substituent to a catalytic or structurally important active-site residue, hydrophobic or π-π stacking contributed by the aryl substituent on the imidazole ring, and, in DNA-binding studies, either intercalation between base pairs or minor-groove association depending on the planarity and length of the hybrid. In silico ADME/toxicity prediction, most often carried out using SwissADME or comparable platforms, has been incorporated into an increasing proportion of recent studies and generally indicates that imidazole-thiadiazole hybrids of moderate molecular weight (below approximately 450 Da) and balanced lipophilicity (calculated logP between roughly 1 and 4) satisfy Lipinski's rule-of-five criteria and are predicted to have acceptable gastrointestinal absorption, though experimental pharmacokinetic confirmation remains comparatively rare across the reports surveyed

7. Relevance To Marketed And Clinically Investigated Agents

The continued interest in this scaffold is reinforced by its proximity to several clinically established or clinically investigated agents. Levamisole, an imidazothiazole approved for use against colon cancer and as an anthelmintic, together with thiabendazole and niridazole, both of which combine imidazole and thiazole/thiadiazole functionality, illustrate that the broader hybrid chemotype explored in this review already has precedent for clinical translation. Sulphonamide-substituted thiadiazoles such as acetazolamide and methazolamide further demonstrate that thiadiazole-containing scaffolds are compatible with sustained clinical use and acceptable safety margins, lending further rationale to continued exploration of imidazole-thiadiazole hybrids as candidates for further development. It is worth emphasising that none of the imidazole-thiadiazole hybrid compounds discussed in the sections above has yet advanced into clinical evaluation in its own right; the clinical precedents cited here involve related but structurally simpler imidazole- or thiadiazole-containing agents rather than the specific fused or conjugated hybrids that are the subject of this review. The relevance of these marketed drugs is therefore best understood as validating the general pharmacophoric territory in which the reviewed hybrids sit, rather than as direct evidence that any specific hybrid analogue is close to clinical translation. Bridging this gap will require the kind of in vivo and pharmacokinetic characterisation discussed in the following section

CHALLENGES AND TOXICOLOGICAL CONSIDERATIONS

Despite the breadth of biological activity reported, several practical limitations recur across this literature. First, the great majority of reported compounds have been evaluated only in vitro, and dose-response or in vivo pharmacokinetic data remain comparatively scarce, limiting confident extrapolation to therapeutic potential. Second, cytotoxicity and selectivity indices relative to non-cancerous or non-target cell lines are inconsistently reported, making it difficult to compare the true therapeutic window across different research groups' series on a like-for-like basis. Third, while in silico ADME prediction is increasingly common, experimental confirmation of metabolic stability, plasma protein binding, and off-target enzyme inhibition (for example, cytochrome P450 interactions) is rarely undertaken at this stage of most of these research programmes. Addressing these gaps will be important for translating the consistently promising in vitro and in silico findings summarised in this review into credible preclinical candidates. A further, more subtle limitation concerns the interpretation of structure-activity relationships derived largely from between-study rather than within-study comparison. Because most individual publications explore a relatively small, focused set of analogues (typically between six and twenty-five compounds per series), many of the broader SAR generalisations presented in this review, including those summarised in Table 1, rest on aggregating trends across multiple independently designed series rather than on a single, internally controlled structure-activity study spanning the full range of substituents discussed. This is a common and largely unavoidable feature of narrative reviews in this area of medicinal chemistry, but it does mean that the SAR trends described here should be read as directional tendencies supported by convergent evidence rather than as rigorously validated quantitative rules, and that future work explicitly designed to test these generalisations within a single, internally consistent series would be of considerable value to the field.

FUTURE DIRECTIONS

Several directions appear well positioned to extend the productive line of research summarised here. Greater emphasis on target-specific design, building on the emerging Pim-1 kinase and carbonic-anhydrase-related work noted above, would allow future series to be optimised against a defined molecular target rather than screened broadly across unrelated assay panels. Systematic head-to-head comparison of fused versus linked hybrid architectures within the same biological assay, which remains rare in the current literature, would help clarify whether the potency advantages generally attributed to fused ring systems are a genuine electronic or geometric effect or simply a reflection of which architecture happens to have been more heavily explored to date. Finally, expanding in vivo pharmacokinetic and toxicological characterisation beyond the still-limited subset of compounds for which such data currently exist would substantially strengthen the translational case for this scaffold. Beyond these scaffold-specific priorities, the broader trajectory of the field also points toward greater integration of computational and experimental workflows from the earliest stages of design rather than as a retrospective rationalisation applied after synthesis and testing are complete. Structure-based virtual screening against a defined target, followed by focused synthesis of only the top-ranked candidates, has already begun to appear in a minority of the most recent reports discussed in this review and represents a more resource-efficient alternative to the broader empirical analogue screening that has historically dominated this literature. Coupling this approach with freely available physicochemical and toxicity-prediction tools at the design stage, rather than only after a compound has already been synthesised and tested, would help future researchers prioritise analogues more likely to combine potency with an acceptable selectivity and safety margin, and would help address the translational gap identified in Section 8.

CONCLUSION

Imidazole-1,3,4-thiadiazole hybrid scaffolds, whether prepared as fused imidazo[2,1-b][1,3,4]thiadiazole bicycles or as linker-tethered conjugates, have generated a decade of consistent and often high-quality biological evaluation data spanning anticancer, antimicrobial, antitubercular, anti-inflammatory, antidiabetic, antioxidant, and antiparasitic activity. Conventional cyclocondensation and Hantzsch-type annulation chemistry remain the dominant synthetic approach to this scaffold, and the structure-activity trends that emerge across independent studies, favouring electron-withdrawing aryl substitution for antimicrobial and anticancer potency and hydroxylated substitution for antioxidant and enzyme-inhibitory activity, are sufficiently reproducible across laboratories to be considered genuine pharmacophoric principles rather than isolated observations. With continued attention to target specificity, in vivo validation, and pharmacokinetic characterisation, this scaffold appears well positioned to continue contributing lead compounds to multiple areas of drug discover.

REFERENCES

1. Korotkov, V.S.; Lukat, P.; Di Lucrezia, R.; Shekhar, A.; Degenhart, C.; Diestel, R.; Bilitewski, U.; Dinkel, K.; Blankenfeldt, W.; Brönstrup, M. An Imidazo[2,1-b][1,3,4]thiadiazole Derivative Inhibits the Virulence Factor α-Hemolysin by Blocking the Pullout of Its Stem Domain. ChemMedChem 2026, 21, e202501098.
2. Cristina, A.; Leonte, D.; Vlase, L.; Bencze, L.C.; Imre, S.; Marc, G.; Apan, B.; Mogoșan, C.; Zaharia, V. Heterocycles 48. Synthesis, Characterization and Biological Evaluation of Imidazo[2,1-b][1,3,4]thiadiazole Derivatives as Anti-Inflammatory Agents. Molecules 2018, 23, 2425.
3. Apan, A.; Casoni, D.; Leonte, D.; Pop, C.; Iaru, I.; Mogoșan, C.; Zaharia, V. Heterocycles 52: The Drug-Likeness Analysis of Anti-Inflammatory Thiazolo[3,2-b][1,2,4]triazole and Imidazo[2,1-b][1,3,4]thiadiazole Derivatives. Pharmaceuticals 2024, 17, 295.
4. Dwarakanath, D.; Nayak, Y.N.; Kulal, A.; Pandey, S.; Pai, K.S.R.; Gaonkar, S.L. In vitro and in silico insights into antimicrobial and anticancer activities of novel imidazo[2,1-b][1,3,4]thiadiazoles. Scientific Reports 2024, 14, 31994.
5. Shekhar, A.; Di Lucrezia, R.; Jerye, K.; et al. Highly Potent Quinoxalinediones Inhibit α-Hemolysin and Ameliorate Staphylococcus aureus Lung Infections. Cell Host & Microbe 2025, 33, 560–572.
6. Heimann, D.; Kohnhäuser, D.; Kohnhäuser, A.J.; Brönstrup, M. Antibacterials with Novel Chemical Scaffolds in Clinical Development. Drugs 2025, 85, 293–323.
7. Bhongade, B.A.; Talath, S.; Gadad, R.A.; Gadad, A.K. Biological activities of imidazo[2,1-b][1,3,4]thiadiazole derivatives: A review. Journal of Saudi Chemical Society 2016, 20, S463–S475.
8. Bhardwaj, V.; Noolvi, M.N.; Jalhan, S.; Patel, H.M. Synthesis and antimicrobial evaluation of new pyridine imidazo[2,1-b]-1,3,4-thiadiazole derivatives. Journal of Saudi Chemical Society 2016, 20, S406–S410.
9. Kumar, R.; Bua, S.; Ram, S.; Del Prete, S.; Capasso, C.; Supuran, C.T.; Sharma, P.K. Benzenesulfonamide bearing imidazothiadiazole and thiazolotriazole scaffolds as potent tumour-associated human carbonic anhydrase IX and XII inhibitors. Bioorganic & Medicinal Chemistry 2017, 25, 1286–1293.
10. Ramprasad, J.; Nayak, N.; Dalimba, U.; Yogeeswari, P.; Sriram, D.; Peethambar, S.K.; Achur, R.; Kumar, H.S.S. One-pot synthesis of new triazole–imidazo[2,1-b][1,3,4]thiadiazole hybrids via click chemistry and evaluation of their antitubercular activity. Bioorganic & Medicinal Chemistry Letters 2015, 25, 4169–4173.
11. Ramprasad, J.; Nayak, N.; Dalimba, U.; Yogeeswari, P.; Sriram, N.; Peethambar, S.K.; Achur, R.; Kumar, H.S.S. Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives. European Journal of Medicinal Chemistry 2015, 95, 49–63.
12. Kumar, S.; Gopalakrishnan, V.; Hegde, M.; Rana, V.; Dhepe, S.S.; Ramareddy, S.A.; Leoni, A.; Locatelli, A.; Morigi, R.; Rambaldi, M.; et al. Synthesis and antiproliferative activity of imidazo[2,1-b][1,3,4]thiadiazole derivatives. Bioorganic & Medicinal Chemistry 2014, 24, 4682–4688.
13. Li Petri, G.; et al. New imidazo[2,1-b][1,3,4]thiadiazole derivatives inhibit FAK phosphorylation and potentiate the antiproliferative effects of gemcitabine through modulation of the human equilibrative nucleoside transporter-1 in peritoneal mesothelioma. Anticancer Research 2020, 40, 4913–4919.
14. Taflan, E.; et al. Novel imidazo[2,1-b][1,3,4]thiadiazole (ITD) hybrid compounds: Design, synthesis, efficient antibacterial activity and antioxidant effects. Bioorganic Chemistry 2019, 89, 102998.
15. Narasimha Rao, M.P.; et al. Synthesis of imidazo-thiadiazole linked indolinone conjugates and evaluation of their microtubule network disrupting and apoptosis inducing ability. Bioorganic Chemistry 2018, 76, 420–436.
16. Fascio, M.L.; Sepúlveda, C.S.; Damonte, E.B.; D'Accorso, N.B. Synthesis and antiviral activity of some imidazo[1,2-b][1,3,4]thiadiazole carbohydrate derivatives. Carbohydrate Research 2019, 480, 61–66.
17. Kadi, A.A.; et al. Synthesis, antimicrobial and anti-inflammatory activities of novel 5-(1-adamantyl)-1,3,4-thiadiazole derivatives. European Journal of Medicinal Chemistry 2010, 45, 5006–5011.
18. Sireesha, R.; et al. Synthesis of substituted aryl incorporated oxazolo[4,5-b]pyridine-triazole derivatives: Anticancer evaluation and molecular docking studies. Polycyclic Aromatic Compounds 2023, 43, 915–932.
19. Alminderej, F.M.; et al. Synthesis and cytotoxic activity of new 1,3,4-thiadiazole Thio glycosides and 1,2,3-triazolyl-1,3,4-thiadiazole N-glycosides. Molecules 2019, 24, 3738.
20. Ragha Suma, V.; Sreenivasulu, R.; Subramanyam, M.; Rao, K.R.M. Design, synthesis, and anticancer activity of amide derivatives of structurally modified combretastatin-A4. Russian Journal of General Chemistry 2019, 89, 499–504.
21. Yang, L.; et al. Synthesis and antimicrobial bioassays of 1,3,4-thiadiazole sulfone derivatives containing amide moiety: A study based on molecular dynamics simulations, MM/GBSA, and molecular docking. Journal of Saudi Chemical Society 2022, 26, 101415.
22. Abo-Bakr, A.M.; Hashem, H.E. New 1,3,4-thiadiazole derivatives: Synthesis, characterization, and antimicrobial activity. Journal of Heterocyclic Chemistry 2019, 56, 1038–1047.
23. Charitos, G.; et al. Synthesis and anticancer activity of novel 3,6-disubstituted 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole derivatives. Arabian Journal of Chemistry 2019, 12, 4784–4794.
24. Tang, C.; et al. Discovery of novel carbazole derivatives containing a 1,3,4-thiadiazole moiety as antifungal candidates. Phosphorus, Sulphur, and Silicon and the Related Elements 2023, 198, 627–631.
25. Kumar, D.; et al. Mechanism-based approaches of 1,3,4-thiadiazole scaffolds as potent enzyme inhibitors for cytotoxicity and antiviral activity. Medicine in Drug Discovery 2023, 17, 100150.
26. Blokhina, S.V.; Sharapova, A.V.; Ol'khovich, M.V.; Doroshenko, I.A.; Levshin, I.B.; Perlovich, G.L. Synthesis and antifungal activity of new hybrids of thiazolo[4,5-d]pyrimidines with (1H-1,2,4)triazole. Bioorganic & Medicinal Chemistry Letters 2021, 40, 127944.
27. Gomha, S.M.; et al. Thiazole-based thiosemicarbazones: Synthesis, cytotoxicity evaluation and molecular docking study. Drug Design, Development and Therapy 2021, 15, 659–677.
28. Hassan, A.; et al. Design and biological evaluation of 3-substituted quinazoline-2,4(1H,3H)-dione derivatives as dual c-Met/VEGFR-2-TK inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry 2023, 38, 2189578.
29. Bedard, P.L.; Hyman, D.M.; Davids, M.S.; Siu, L.L. Small molecules, big impact: 20 years of targeted therapy in oncology. The Lancet 2020, 395, 1078–1088.
30. Ibrahim, A.O.A.; et al. New quinazolin-2,4-dione derivatives incorporating acylthiourea, pyrazole and/or oxazole moieties as antibacterial agents via DNA gyrase inhibition. RSC Advances 2024, 14, 17158–17169.
31. Tatar, E.; et al. Design, synthesis, and molecular docking studies of a conjugated thiadiazole-thiourea scaffold as antituberculosis agents. Biological & Pharmaceutical Bulletin 2016, 39, 502–515.
32. Gariganti, N.; et al. Design, synthesis, anticancer activity of new amide derivatives derived from 1,2,3-triazole-benzofuran hybrids: insights from molecular docking, molecular dynamics simulation and DFT studies. Journal of Molecular Structure 2023, 1273, 134250.
33. Dwarakanath, D.; et al. Synthesis, computational studies and evaluation of benzisoxazole-tethered 1,2,4-triazoles as anticancer and antimicrobial agents. Journal of Molecular Structure 2024.
34. 34. Zeeshan, R.; Mutahir, Z. Cancer metastasis—Tricks of the trade. Bosnian Journal of Basic Medical Sciences 2017, 17, 172–182.
35. Sun, G.; et al. Antibiotic resistant bacteria: A bibliometric review of literature. Frontiers in Public Health 2022, 10, 1002015.
36. Toma, A.; Mogosan, C.; Vlase, L.; Leonte, D.; Zaharia, V. Heterocycles 39. Synthesis, characterization and evaluation of the anti-inflammatory activity of thiazolo[3,2-b][1,2,4]triazole derivatives bearing pyridin-3/4-yl moiety. Medicinal Chemistry Research 2017, 26, 2602–2613.
37. Cristina, A.; Leonte, D.; Vlase, L.; Bencze, L.C.; Imre, S.; Apan, B.; Mogoșan, C.; Zaharia, V. Heterocycles 46. Synthesis, characterization and biological evaluation of thiazolo[3,2-b][1,2,4]triazoles bearing benzenesulfonamide moiety. Farmacia 2018, 66, 883–893.
38. Roy, D.; Patel, C. Revisiting the use of quantum chemical calculations in LogP octanol-water prediction. Molecules 2023, 28, 801.
39. Han, R.; Yoon, H.; Kim, G.; Lee, H.; Lee, Y. Revolutionizing medicinal chemistry: The application of Artificial Intelligence (AI) in early drug discovery. Pharmaceuticals 2023, 16, 1259.
40. Daina, A.; Michielin, O.; Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports 2017, 7, 42717.